Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • End date
    Dec 19, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 22 December 2021


The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.

Condition Recurrent Brain Metastases
Treatment Craniotomy, Cesium-131 brachytherapy
Clinical Study IdentifierNCT04690348
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on22 December 2021


Yes No Not Sure

Inclusion Criteria

Adult patients ≥ 18 years of age who are capable of giving consent
Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (>/=95%) resection
Karnofsky Performance Status score (KPS) of ≥70
Ability to undergo brain MRI with gadolinium

Exclusion Criteria

Unable to tolerate MRI or CT imaging
Pregnancy (patients must have a negative pregnancy test within 30 days of the operation)
Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable)
Diagnosis of leptomeningeal carcinomatosis or >5 additional active or untreated CNS lesions for a total of >6 active lesions
Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2
Apposition of tumor margin to brainstem or optic apparatus
Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency
Urgent surgery required prior to availability of brachytherapy
Intraoperative Exclusion Criterion
Patients will be excluded if intraoperative pathology is not consistent with >/=5% viable metastatic disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note